Emerging role of non-coding RNAs in glucose metabolic reprogramming and chemoresistance in colorectal cancer

Shushan Yan1†, Shufeng Wang2†, Xinyi Wang3†, Wenqing Dai4†, Jinjin Chu4, Min Cheng5, Zhiliang Guo6* and Donghua Xu4,7*

1Department of Gastrointestinal and Anal Diseases Surgery of the Affiliated Hospital, Weifang Medical University, Weifang, China, 2Medical Experimental Training Center, Weifang Medical University, Weifang, China, 3Clinical Medicine of Basic Medical School, Shandong First Medical University, Jinan, China, 4Central Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang, China, 5Department of Physiology, Weifang Medical University, Weifang, China, 6Department of Spine Surgery, The 80th Group Army Hospital of Chinese People’s Liberation Army (PLA), Weifang, China, 7Department of Rheumatology of the First Affiliated Hospital, Weifang Medical University, Weifang, China

Metabolic reprogramming plays a critical role in colorectal cancer (CRC). It contributes to CRC by shaping metabolic phenotypes and causing uncontrolled proliferation of CRC cells. Glucose metabolic reprogramming is common in carcinogenesis and cancer progression. Growing evidence has implicated the modifying effects of non-coding RNAs (ncRNAs) in glucose metabolic reprogramming and chemoresistance in CRC. In this review, we have summarized currently published studies investigating the role of ncRNAs in glucose metabolic alterations and chemoresistance in CRC. Elucidating the interplay between ncRNAs and glucose metabolic reprogramming provides insight into exploring novel biomarkers for the diagnosis and prognosis prediction of CRC.

KEYWORDS
Circular RNA, colorectal cancer, glucose metabolism, long noncoding RNA, metabolic reprogramming, microRNA

Abbreviations: CRC, colorectal cancer; ncRNAs, non-coding RNAs; PPP, pentose phosphate pathway; circRNA, circular RNA; lncRNA, long noncoding RNA; miRNA, microRNA; GLUT1, glucose transporter 1; HIF-1α, hypoxia-induced factor-1α; GYS1, glycogen synthase; PDHX, pyruvate dehydrogenase protein X component; 3′UTR, 3′ untranslated region; PKM, pyruvate kinase isozyme; HK1, hexokinase 1; HK2, hexokinase 2; SDHB, succinate dehydrogenase-B; PRKAA2, AMP-Activated Protein Kinase; GLUT1, glucose transporter 1; PDK2, pyruvate dehydrogenase kinase isoform 2; LDHA, Lactate dehydrogenase A; EVs, extracellular vesicles; HIPK3, homeodomain-interacting protein kinase; cerRNA, competitive endogenous RNA; TAB3, transforming growth factor β-activated kinase-binding protein 3; YY1, Yin Yang 1; UBE2Q1, ubiquitin-conjugating enzyme EZQ family member 1; ATP, adenosine triphosphate; OLA1, glycolysis by recruiting Obg-like ATPase 1; AMPK, adenosine monophosphate-activated protein kinase; TAM, tumor-associated macrophage; ACTG1, γ-Actin Gene; FOXM1, forkhead box M1.
Introduction

Colorectal cancer (CRC) is one of the most common digestive cancers, with increasing incidence and mortality in young adults in particular (1, 2). CRC is the secondly most common cancer worldwide with the incidence and mortality of 12% and 7%, respectively. Identifying novel biomarkers for the early diagnosis and treatment of CRC is very important. Targeted therapy for CRC has been promoted with progress in the high-throughput sequencing technology. Glucose metabolic reprogramming is a hallmark of cancer, which plays a critical role during carcinogenesis (3). The glucose metabolic pathways primarily include aerobic glycolysis, gluconeogenesis, and pentose phosphate pathway (PPP). Aerobic glycolysis is called Warburg effect, which is common in most aggressive cancer cells. It has been well documented that abnormal aerobic glycolysis is closely related to cancer growth and survival (4). Besides, disorders of glucose metabolic reprogramming in immune cells can lead to microenvironment imbalance and affect anti-tumor immunity (5). Research in metabolomics has suggested those key molecules underlying the metabolic mechanisms would serve as optimal approaches for CRC diagnosis and prognosis prediction. Blocking the glucose metabolic reprogramming in immune cells can help to defend against cancer.

A growing number of studies have implicated that noncoding RNAs (ncRNAs) are involved in tumor initiation and progression, primarily including circular RNA (circRNA), long noncoding RNA (lncRNA) and microRNA (miRNA) (6, 7). The ncRNAs regulatory networks are essential for tumorigenesis, tumor invasion and metastasis. Some ncRNAs act as oncogenic drivers, while some other ncRNAs function as tumor suppressors. They can regulate numerous molecular targets through RNA-RNA or RNA-protein interactions. Increasing evidence has supported that ncRNAs participate in the glucose metabolic reprogramming of cancer by targeting metabolism-associated with genes, such as glucose transporter 1 (GLUT1), hypoxia-induced factor-1a (HIF-1a), and glycogen synthase 1 (GYS1). Some ncRNAs may also influence the chemoresistance to CRC. Accumulated studies have investigated the crucial role of ncRNAs in regulating glucose metabolism and chemoresistance in CRC in the past few years (8–10). The identification of ncRNA-based glucose metabolism regulatory networks is currently emerging as a promising approach in the field of early screening and targeted therapy of CRC. In this review, we aim to elucidate the molecular targets regulated by ncRNAs that might be involved in the glucose metabolic reprogramming and chemoresistance of CRC.

Regulation of glucose metabolic reprogramming by miRNAs

It has been well documented that abnormal glucose metabolism is one of the leading causes for CRC development (11). Usually, normal tissues acquire energy through the aerobic oxidative phosphorylation but undergo anaerobic glycolysis under hypoxia. However, the main way for acquiring energy of cancer cells is aerobic glycolysis even under the condition of adequate oxygen. Aerobic glycolysis is typical in the metabolic reprogramming of CRC. Abnormal glucose metabolism in CRC cells is primarily attributed to the mitochondrial dysfunction, abundant activation of key enzymes involved in glycolysis, altered isozyme profiles and dysregulated glucose metabolic signaling pathways (12, 13).

Accumulated studies have demonstrated that miRNAs play important roles in CRC by transcriptionally regulating specific miRNAs (14). They are single-stranded noncoding small RNAs with about 22 nucleotides. MiRNAs confer their biological effects by specifically complementary recognition of the miRNA response elements to the 3′ untranslated region (3′UTR) of miRNAs. Many miRNAs have been implicated in the glucose metabolic reprogramming. With advance in high-throughput technology, some miRNAs have been demonstrated to confer effects on the metabolic interactions between CRC cells and gut microbiota, suggesting the critical role of miRNAs in mediating tumor-microbiota metabolic interplays (15). To the best of our knowledge, butyrate produced by the gut microbiota provides approximately 70% of energy needs for the colonic epithelial cells. Aberrant expression of miRNAs can influence glucose metabolism mediated by butyrate in cancer cells through the gut-brain axis (16–18). Nonetheless, little is known of the potential interactions between miRNAs and gut microbiota in CRC glucose metabolic reprogramming. Current progress in the role of miRNAs in the glucose metabolism of CRC has been summarized in Table 1. The association between miRNAs and gut microbiota-mediated glucose metabolism in CRC has also been elucidated in the following context.

Glucose metabolism-associated miRNAs dysregulated in CRC

There are many glucose metabolism-associated miRNAs dysregulated in CRC, such as miR-4999-5p, miR-181d, and miR-24 (19–21) (Table 1). Increased expression of miR-4999-5p has been demonstrated in CRC, which can also modulate the glucose metabolic reprogramming of CRC cells by targeting the critical molecule of mTOR signaling pathway, namely, AMP-Activated Protein Kinase (PRKA2) (19). It promotes glycolysis in CRC cells (19). MiR-26a overexpression can increase the production of pyruvate but decrease the generation of acetyl coenzyme A by suppressing pyruvate dehydrogenase protein X component (PDHX) in HCT116 cells, which suggests the critical of miR-26a in reprogramming glucose metabolism in CRC (22). Jin F and the colleagues have illustrated that HIF-1α-induced miR-23a~27a~24 cluster promoted the propagation of CRC by reprogramming glucose metabolism from oxidative phosphorylation to glycolysis.
MiRNAs of miR-124, miR-137 and miR-340 have been documented to regulate Warburg effect by alternatively splicing pyruvate kinase isozyme (PKM) gene and controlling the ratio of PKM1/PKM2 in CRC cells (29). Another study by Qiu Z et al. have reported that miR-124 reduced PPP by regulating phosphoribosyl pyrophosphate synthetase 1 (PRPS1) and ribose-5-phosphate isomerase-A (RPIA) in CRC (33). Taken together, these findings have suggested the pivotal role of miRNAs in regulating glucose metabolism in CRC. MiRNAs exert biological effects on the glucose metabolism of CRC cells by regulating different genes. It must be mentioned that the targeted genes participating in the glucose metabolic reprogramming of CRC are diverse and complicated. The same miRNA may have different targets, while some different miRNAs may simultaneously target the same gene.

### Table 1: MiRNAs involved in CRC glucose metabolism.

| MiRNA          | Expression (Up/Down) | Target               | Effect                                                                 | Reference                                |
|----------------|----------------------|----------------------|------------------------------------------------------------------------|------------------------------------------|
| miR-4999-5p    | Up                   | PRKAA2               | Predicting CRC survival outcome; Promoting glycolysis and CRC growth   | Zhang QW, et al. (19)                    |
| miR-26a        | NA                   | PDHX                 | Promoting pyruvate accumulation and reducing acetyl coenzyme A production | Chen B, et al. (22)                     |
| miR-143        | Down                 | NA                   | Inhibiting CRC cells proliferation and glucose uptake                  | Zhao J, et al. (23)                     |
| miR-149-3p     | NA                   | PDK2                 | Increasing 5-FU-induced CRC cells apoptosis and inhibiting glucose metabolism | Liang Y, et al. (24)                    |
| miR-24         | Up                   | VHL                  | Switching metabolism from oxidative phosphorylation to glycolysis in CRC | Jin F, et al. (20)                      |
| miR-181d       | Up                   | CRY2 and FBXL3       | Stabilizing c-myc and promoting the glucose consumption and the production of lactate in CRC | Guo X, et al. (21)                      |
| miR-488        | Down                 | NA                   | Inhibiting the chemoresistance and glycolysis of CRC                   | Deng X, et al. (25)                     |
| miR-125b-5p    | NA                   | NA                   | Inhibiting lactate generation and chemoresistance to oxaliplatin and 5-fluorouracil in CRC | Park GB et al. (26)                     |
| miR-339-5p     | NA                   | hnRNPA1 and PTP1     | Inhibiting CRC cells glycolysis and growth by downregulating PKM2      | Wu H, et al. (27)                       |
| miR-328        | NA                   | GLUT1                | Regulating the Warburg effect by targeting GLUT1 in CRC                | Santasusagna S et al. (28)              |
| miR-124, miR-137 and miR-340 | NA | PKM          | Switching PKM1/PKM2 ratio and regulating glycolysis rate of CRC cells | Sun Y, et al. (29)                      |
| miR-142-5p     | Up                   | SDHB                 | Facilitating aerobic glycolysis of CRC cells via targeting SDHB         | Liu S, et al. (30)                      |
| miR-374a       | Down                 | LDHA                 | Refining aerobic glycolysis via targeting LHHA                         | Wang J, et al. (31)                     |
| miR-122        | NA                   | HK2                  | Down-regulating HK2 and affecting glucose metabolism                   | Gregeresen LH, et al. (32)              |
| miR-34a        | NA                   | PRPS1 and RPIA       | Inhibiting lactate production and PPP                                   | Qiu Z, et al. (33)                      |
| miR-98         | Down                 | HK2                  | Functioning as a tumor suppressor and inhibiting Warburg effect        | Zhu W, et al. (34)                      |
| miR-206        | Down                 | hnRNPA1              | Suppressing PKM2 expression and attenuating Warburg effect of CRC cells | Fu R, et al. (35)                       |
| miR-500a-3p    | Down                 | CDK6                 | Inhibiting aerobic glycolysis and CRC progression                      | Liu Y, et al. (36)                      |
| miR-122        | NA                   | PKM2                 | Inhibiting aerobic glycolysis in 5-FU-resistant CRC cells              | He J, et al. (37)                       |
| miR-34a        | NA                   | LDHA                 | Mediating inhibition of glucose metabolism in 5-FU-resistant CRC cells | Li X, et al. (38)                       |
| miR-135b       | NA                   | SPOCK1               | Promoting the Warburg effect in CRC                                   | Babaei-Jadidi R, et al. (39)            |
| miR-4458       | Down                 | HK2                  | Refining the glycolysis and lactate production in CRC cells            | Qin Y, et al. (40)                      |
| miR-27a        | Up                   | FBXW7                | Forcing the aerobic glycolytic metabolism in CRC                       | Barisicano G, et al. (41)               |
| let-7a         | Up                   | SNAP23               | Promoting EV secretion of CRCs and enhancing mitochondrial oxidative phosphorylation | Liu Y, et al. (42)                      |
| miR-101        | NA                   | EZH2 and OGT         | MiR-101-O-GlcnAc/EZH2 regulatory feedback circuit regulating CRC metabolic reprogramming | Jiang M, et al. (43)                    |
| miR-101-3p     | Up                   | HIPK3                | Promoting aerobic glycolysis by targeting HIPK3 in CRC                | Tao L, et al. (44)                      |

NA, not available.
dehydrogenase A (LDHA). A number of miRNAs are implicated in targeting the key enzymes or transporters involved in cancer cells glycolysis (Table 1 and Figure 1). Zhao J et al. have reported that miR-143 downregulated the expression of GLUT1 and inhibited glucose uptake in CRC cells (23). Besides, miR-328 is also involved in regulating the Warburg effect by targeting GLUT1 in CRC cells (28). PKM2 is another key enzyme involved in glycolysis. MiR-339-5p has been well documented to restrain CRC cells glycolysis and growth by downregulating PKM2 (27). Similarly, the study by Fu R and the colleagues have found that hnRNPA1 was a direct target of miR-206, which suppressed PKM2 expression and attenuated Warburg effect of CRC cells (35). Moreover, the upregulation of miR-142-5p inhibits the intake of oxygen but facilitates aerobic glycolysis of CRC cells by targeting the key enzyme of succinate dehydrogenase-B (SDHB) (30). Elevated glucose consumption and lactate generation is found in miR-142-5p-treated CRC cells (30). LDHA is identified as the targeted gene of miR-374a, which refines the aerobic glycolysis of CRC cells (31). Apart from the above-mentioned key enzymes and transporters in glycolysis, hexokinase 2 (HK2) is a critical rate-limiting enzyme for glycolysis. It has been demonstrated to be the direct target of miR-143, miR-4458, and miR-98 in CRC cells (32, 34). Suppression of miR-143 contributes to the shift towards aerobic glycolysis in CRC via targeting HK2 (32). MiR-4458 is demonstrated to prevent from glycolysis and lactate production by directly regulating HK2, which thus inhibits the progression of CRC (40). Accordingly, those aberrantly expressed miRNAs and targeted molecules involved in glycolysis would serve as helpful targets for CRC.

In the last decade, some exosomes-delivering miRNAs have been well documented to participate in regulating glucose metabolism in CRC by targeting key metabolic genes of HIF-1α and PGK1, such as exosomal miR-6869-5p, miR-8075, miR-5787, and miR-548c-5p (45). Let-7a is demonstrated to be enriched in extracellular vesicles (EVs) derived from CRC cells (42). The EVs-derived let-7a can promote the mitochondrial oxidative phosphorylation via downregulating SNAP23 in CRC cells (42). Tao L et al. have reported that exosomal miR-101-3p acts as an oncomiR in CRC, which promoted glycolysis and influenced metabolic homeostasis by targeting hemeodomain-interacting protein kinase (HIPK3) in CRC cells (44). However, how those miRNAs being encapsulated in EVs and transferred to cancer cells remains largely unknown. More future studies are encouraged to elucidate the underlying molecular mechanism of EVs-delivering miRNAs in regulating glucose metabolic reprogramming in CRC.

**Altering effects of miRNAs on chemoresistance and glycolysis in CRC**

Most interestingly, certain miRNAs are involved in regulating the chemoresistance and glucose metabolism in CRC. MiR-149-3p has been found to promote 5-Fluorouracil (5-FU)-induced CRC cells apoptosis and inhibit the glucose metabolism by targeting PDK2 (24). MiR-488 is obviously decreased in metastatic/recurrent CRC, which can also refine the chemoresistance and glycolysis of CRC by targeting a key enzyme involved in glucose metabolism, namely,
Regulation of glucose metabolic reprogramming by IncRNAs

Glucose metabolism-associated LncRNAs dysregulated in CRC

Currently identified IncRNAs associated with glucose metabolism in CRC have been summarized in Table 2. As shown in Figure 1, some IncRNAs exert effects through RNA-protein or RNA-polypeptide interactions, while some IncRNAs regulate targeted genes via lncRNA-miRNA-mRNA competitive endogenous RNA (ceRNA) regulatory networks (46–50). A recent study has supported that IncRNA ZEB2-AS1 promoted glycolysis and regulated the expression of transforming growth factor-β-activated kinase-binding protein 3 (TAB3) by adsorbing miR-188 (51). A LIN00265/miR-216b-5p/TRIM44 axis has been characterized to be targeted by miR-122 involved in regulating glucose metabolism of CRC cells (37). Furthermore, miR-122 can inhibit glycolysis and serve as a useful therapeutic strategy overcoming 5-FU chemoresistance in CRC (37). Apart from miR-122, miR-34a is also implicated in regulating the sensitivity to 5-FU in CRC by repressing glycolysis, suggesting the critical role of miRNAs during interactions between chemoresistance and glycolysis (38). Taken together, some miRNAs can function as therapeutic targets in patients with chemoresistant CRC, including miR-149-3p, miR-122 and miR-34a. Nevertheless, the possible regulatory mechanism in mediating chemoresistance and glucose metabolism balance in CRC needs to be investigated in the future.

LncRNAs and key enzymes/transporters in CRC glycolysis

LncRNA RAD51-AS1 has been shown to hamper glucose consumption and lactate production by inhibiting the key glycolysis enzyme HK2 and GLUT1 in CRC cells (53). Similar findings have been demonstrated in other studies published previously (59–61). LncRNA UCA1 is found to promote glycolysis via upregulating HK2 and LDHA in CRC cells (59). LncRNA HULC has been demonstrated to bind LDHA and PKM2 and thus promote aerobic glycolysis (74). Yan T, et al. (60) have reported that LncSLCC1 was upregulated in CRC and promoted glycolysis by transcriptionally activating HK2 (60). Another well documented lncRNA interacting with HK2 is LncRNA FGD5-AS1, which has been illustrated to promote glycolysis through the miR-330-3p-HK2 signaling network (67). Moreover, a lncRNA DANC-miR-125b-5p-HK2 axis has been well established in colon cancer cells, which can promote aerobic glycolysis (75). Additionally,
| LncRNA      | Expression (Up/Down) | Targeted miRNA | Targeted mRNA | Effect                                                                 | Reference |
|------------|----------------------|----------------|---------------|----------------------------------------------------------------------|-----------|
| RAD51-AS1  | Down                 | miR-29b        | c-3p/NDRG2    | Inhibiting cell proliferation, migration, invasion and glycolysis; promoting CRC progression via miR-29b/c-3p/NDRG2 signaling axis | Li C, et al. (53) |
| IncARSR    | Up                   | miR-34a-5p     | HK1           | Sponging miR-34a-5p and promoting HK1-related aerobic glycolysis in vitro and in vivo in CRC | Li S, et al. (62) |
| MCF2L-AS1  | Up                   | miR-874-3p     | FOXM1         | Enhancing the glucose consumption and lactate production via upregulating GLUT1 and LDHA | Zhang Z, et al. (63) |
| ZEB2-AS1   | Up                   | miR-188        | TAB3          | Promoting aerobic glycolysis via miR-188/TAB3 axis                   | Li Y, et al. (51) |
| HCG11      | Up                   | miR-144-3p     | PDK4          | Promoting glucose metabolism and 5-FU sensitization through miR-144-3p-PDK4-glucose metabolism pathway in CRC | Cui Z, et al. (64) |
| GLOCI      | Up                   | NA             | c-Myc         | Enhancing aerobic glycolysis by stabilizing c-Myc                    | Tang J, et al. (8) |
| MIR17HG    | Up                   | miR-138-3p     | HK1           | Promoting CRC liver metastasis and glycolysis through p38/Elk-1 signaling pathway | Zhao S, et al. (65) |
| LINC0025S  | Up                   | miR-338-3p     | UBE2Q1        | Promoting hypoxia-induced glycolysis by activating HIF-1α in CRC     | Meng F, et al. (46) |
| ZFAS1      | Up                   | NA             | OLA1          | Accelerating ATP hydrolysis and the Warburg effect in an m6A-dependent manner | Lu S, et al. (47) |
| Inc-RP11-536K7.3 | Up | NA | USP7 | Promoting glycolysis, angiogenesis, and chemo-resistance via SOX2/USP7/HIF-1α axis in CRC | Li Q, et al. (66) |
| PTG3HP     | Up                   | NA             | YAP1          | Facilitating glycolysis and CRC proliferation and progression via regulating YAP1 | Zheng Y, et al. (48) |
| FGDS-AS1   | NA                   | miR-330-3p     | HK2           | Enhancing glycolysis through the miR-330-3p-HK2 axis and promoting 5-FU resistance in CRC | Gao S, et al. (67) |
| MIR31HG    | Up                   | miR-361-3p     | YY1           | Promoting glycolysis and metastasis of CRC via MIR31HG-miR-361-3p-YY1 axis | Guo T, et al. (56) |
| COL4A2-AS1 | Up                   | miR-20b-5p     | HIF-1α        | Promoting aerobic glycolysis of CRC cells via miR-20b-5p/HIF-1α axis | Yu Z, et al. (68) |
| UCA1       | Up                   | NA             | HK2 and LDHA  | Contributing to Taxol resistance and promoting aerobic glycolysis in CRC | Shi H, et al. (59) |
| IncSLCC1   | Up                   | NA             | HK2           | Promoting aerobic glycolysis and CRC growth                          | Yan T, et al. (60) |
| XIST       | Up                   | miR-137        | PKM2/PKM1     | Elevating PKM2/PKM1 ratio and promoting 5-FU/cisplatin-resistance and glycolysis in CRC | Zheng H, et al. (69) |
| ENO1-IT1   | NA                   | NA             | ENO1          | Promoting F. nucleatum-mediated glycolysis and oncogenesis via ENO1 pathway in CRC | Hong J, et al. (58) |
| MIAT       | Up                   | miR-488-3p     | IGF1R         | Inhibiting CRC glycolysis via sponging miR-488-3p                    | Liu Y, et al. (49) |
| SPRY4-IT1  | Up                   | NA             | PDK1          | Promoting aerobic glycolysis and CRC growth                          | Liu S, et al. (70) |
| KCNQ1OT1   | Up                   | NA             | HK2           | Promoting colorectal carcinogenesis and glycolysis by targeting HK2  | Chen C, et al. (61) |
| SNHG6      | Up                   | NA             | PKM2/PKM1     | Elevating PKM2/PKM1 ratio and promoting glycolysis in CRC            | Lan Z, et al. (71) |
| MEG3       | Down                 | NA             | c-Myc         | Inhibiting glycolysis, glycolytic capacity, and lactate production in CRC cells | Zuo S, et al. (55) |
| HNF1A-AS1  | Up                   | miR-124        | MYO6          | Enhancing glycolysis via miR-124/MYO6 axis in CRC                   | Guo X, et al. (50) |
| LINRIS     | Up                   | NA             | IGF2BP2       | Promoting glycolysis via LINRIS-IGF2BP2-MYC axis in CRC             | Wang Y, et al. (54) |
| LINC00265  | Up                   | miR-216b-5p    | TRIM44        | Increasing glucose uptake, pyruvate and lactate production in CRC    | Sun S, et al. (52) |
| MAFG-AS1   | Up                   | miR-147b       | NDUF4A        | Promoting glycolysis via targeting miR-147b/NDUF4A                  | Cui S, et al. (72) |

(Continued)
MCF2L-AS1 is found to be enriched in tissues of CRC, which enhances the glycolysis of CRC cells via MCF2L-AS1/miR-874-3p/FOXM1 ceRNA axis and upregulates GLUT1 and LDHA (63). It has been elaborated that lncARSR can sponge miR-34a-5p and promote hexokinase 1 (HK1)-mediated glycolysis in CRC (62). Besides, high level of lncARSR predicts poor survival of CRC (62). Similarly, the study by Zhao S, et al. has shown the evidence that lncRNA MIR17HG facilitated HK1 expression by acting as a ceRNA for miR-138-5p (65). MIR17HG promotes glycolysis and the liver metastasis of CRC (65). Furthermore, LncRNA SPRY4-IT1 has been demonstrated to enhance CRC cell growth and glycolysis by promoting phosphoinositide-dependent kinase 1 (PDK1) expression (70). Similar altering effect of lncRNA MAFG-AS1 has been illustrated to promote PDK1 expression in CRC (72). Taken together, lncRNAs participate in CRC glycolysis primarily by regulating the key glycolysis-associated enzymes of HK1, HK2, PDK1, and crucial transporter GLUT1 (Figure 1). Elucidating the underlying mechanism and targets of lncRNAs in regulating glycolysis is helpful for exploring more effective strategies for the diagnosis and treatment of CRC.

PKM2

As a key enzyme in glycolysis, PKM2 has been demonstrated to be regulated by several lncRNAs. For instance, lncRNA XIST facilitates glycolysis of CRC cells by upregulating PKM2 through XIST/miR-137/PKM2 axis (69). Similarly, lncRNA SNHG6 plays a critical role in the glucose metabolism of CRC, which specifically splices PKM mRNA, increases PKM2/PKM1 ratio and promotes the glycolysis in CRC (71). FEZF1-AS1 has been shown to promote the pyruvate kinase activity and aerobic glycolysis by targeting PKM2 in CRC cells (73). Taken together, lncRNA–PKM2 axis is critical in regulating CRC glycolysis.

Involvement of LncRNAs in regulating CRC chemoresistance and glycolysis

Accumulating studies have suggested the critical role of lncRNAs in chemoresistance in cancer. Some lncRNAs have also been implicated to regulate the glucose metabolism and chemoresistance in CRC. The study by Li Q et al. have identified an oncogenic gene lnc-RP11-536 K7.3, which enhanced the glycolysis and chemoresistance to oxaliplatin in CRC via SOX2/USP7/HIF-1α signaling axis (66). Pyruvate dehydrogenase kinase 4 (PDK4) is a crucial enzyme for glucose metabolism. LncRNA HCG11 has been validated to facilitate 5-FU resistance by sponging miR-144-3p and upregulating PDK4 in CRC (64). Similar to HCG11, lncRNA FGD5-AS1 promotes glycolysis and 5-FU resistance of CRC cells by acting as a ceRNA for miR-330-3p (67). Besides, lncRNA UCA1 is documented to contribute to paclitaxel (Taxol)-resistance and promote glycolysis by facilitating the expression of HK2 and LDHA in CRC (59). Moreover, lncRNA XIST is demonstrated to promote 5-FU/cisplatin-resistance and glycolysis in CRC by increasing the ratio of PKM2/PKM1, while miR-137 mimics can alleviate the facilitating effect of XIST (69). Accordingly, lncRNAs involved in regulating CRC glycolysis and chemoresistance will serve as novel anticancer strategies for CRC in the future.
Regulation of glucose metabolic reprogramming by circRNAs

Dysregulated circRNAs Associated with glucose metabolic reprogramming in CRC

Table 3 has shown the aberrantly expressed circRNAs in CRC. Some circRNAs function as onco-circRNAs, while some others act as cancer-suppressors. CircTADA2A has been reported to inhibit the cell cycle, glycolysis of CRCs but significantly promote CRC cells apoptosis (76). CircNOX4 has been identified as an oncogenic circRNA in CRC by enhancing the glycolysis and controlling the expression of CDC28 protein kinase regulatory subunit 1B (CKS1B) in CRC cells through the circNOX4/miR-485-5p/CKS1B axis (77). Knockdown of circ_0000231 can inhibit glycolysis and the growth of CRC cells by sponging miR-502-5p, which binds to myosin VI (MYO6) (78). A recent published study has suggested that circPLCE1 could also function as a ceRNA binding with miR-485-5p and expedite epithelial mesenchymal transformation (EMT) and glycolysis of CRC cells (79). Besides, circPLCE1 is capable of promoting tumor-associated macrophage (TAM) polarization towards M2 via upregulating γ-Actin Gene (ACTG1) but inhibiting miR-485-5p in CRC (79). Furthermore, silencing of circ-RNF121 represses the growth and glycolysis of CRC cells, which can act as a sponge for miR-1224-5p and target forkhead box M1 (FOXM1) (80). Most importantly, circ-RNF121 can be packaged into exosomes and thus contributes to intercellular communications and regulates glycolysis in CRC (80). Apart from circ-RNF121, exosomes-delivering ciRS-122 is involved in promoting the glycolysis of CRC cells through ciRS-122/miR-122/PKM2 ceRNA network (81). Accordingly, circRNA is capable of acting as a sponge of specific miRNA and thus participates in the Warburg effect by regulating glycolysis-associated genes in CRC (Figure 1). Some circRNAs can be delivered by exosomes and mediate glucose metabolic reprogramming in CRC, including circ-RNF121 and ciRS-122 (Figure 1).

CircRNAs and key enzymes/transporters in glycolysis

The study by Zhang Z et al. has demonstrated that circDENND4C was upregulated in CRC, which promoted the proliferation, migration, and glycolysis of CRC cells by acting as a ceRNA for miR-760 and regulating GLUT1 (82). Besides, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isotype 3 (PFKFB3) is a pivotal enzyme for glucose metabolism. Gao Y and the colleagues have found circSAMD4A could facilitate the expression of PFKFB3 and promote glycolysis by sponging miR-545-3p (83). Moreover, PKM2 is another crucial enzyme for glycolysis in cancer. Exosomes from oxaliplatin-resistant CRC cells can deliver ciRS-122 to oxaliplatin-sensitive cells, which thereby upregulates PKM2 expression and promotes the glycolysis and drug resistance of CRC cells (81). Li Q et al. have reported that circACC1 played a critical role during the metabolic reprogramming of CRC cells by regulating adenosine monophosphate-activated protein kinase (AMPK) (84). CircACC1 enhances both fatty acid β-oxidation and glycolysis in CRC cells by activating AMPK (84). Taken together, those key

---

**Table 3** CircRNAs involved in CRC glucose metabolism.

| CircRNA       | Expression (Up/Down) | Targeted miRNA | Targeted mRNA | Effect                                                                 | Reference                     |
|--------------|----------------------|----------------|---------------|----------------------------------------------------------------------|-------------------------------|
| circDENND4C  | Up                   | miR-760        | GLUT1         | Promoting the proliferation, migration, and glycolysis of CRC cells   | Zhang Z, et al. (82)          |
| circTADA2A   | Down                 | miR-374a-3p    | KLF14         | Inhibiting cell cycle, glycolysis and promoting the CRC cells apoptosis| Zheng L, et al. (76)          |
| circNOX4     | Up                   | miR-485-5p     | CKS1B         | Serving as an oncogenic circRNA and promoting the glycolysis of CRC cells through miR-485-5p/CKS1B signaling | Wang X, et al. (77)           |
| circ_0000231 | Up                   | miR-502-5p     | MYO6          | Promoting glycolysis and MYO6 expression through sponging miR-502-5p  | Liu Y, et al. (78)            |
| circPLCE1    | Up                   | miR-485-5p     | ACTG1         | Promoting epithelial mesenchymal Transformation, M2 polarization and glycolysis in CRC | Yi B, et al. (79)             |
| circSAMD4A   | Up                   | miR-545-3p     | PFKFB3        | Contributing to 5-Fu resistance and promoting glycolysis              | Gao Y, et al. (83)            |
| circ-RNF121  | Up                   | miR-1224-5p    | FOXM1         | Promoting CRC growth and glycolysis                                 | Jiang Z, et al. (80)          |
| ciRS-122     | NA                   | miR-122        | PKM2          | Encapsulating in exosomes and promoting the glycolysis and chemoresistance of CRC cells | Wang X, et al. (81)          |
| circACC1     | Up                   | NA             | AMPK          | Promoting the glycolysis and fatty acid β-oxidation                  | Li Q, et al. (84)             |

NA, not available.
enzymes or transporters targetedly regulated by circRNAs have suggested novel markers for CRC diagnosis and treatment by controlling glucose metabolism.

**Effects of circRNAs on chemoresistance in CRC by regulating glycolysis**

Some dysregulated circRNAs participate in regulating chemoresistance and glycolysis in CRC, such as circSAMD4A (83) and ciRS-122 (81). CircSAMD4A contributes to 5-Fu resistance via targeting miR-545-3p/PFKFB3 and regulating glycolysis of CRC cells, while knockdown of circSAMD4A improves the sensitivity of 5-Fu (83). Exosomes-derived ciRS-122 is capable of promoting glycolysis and making chemosensitive-CRC cells transform into chemoresistant-CRC cells via miR-122/PKM2 axis (81). Accumulating studies have implicated the important role of circRNA in regulating immune metabolic reprogramming and immune microenvironment balance in carcinogenesis (85). CircPLCE1 has been documented to promote TAM polarization towards M2 through miR-485-5p/ACTG1 axis in CRC, which plays a critical role in regulating CRC immune microenvironment balance (79). All these findings have provided a promising circRNA-targeted therapy for CRC by shaping cancer glucose metabolism, immune microenvironment balance and cancer cells chemoresistance.

**Concluding remarks and future directions**

In conclusion, ncRNA-based glucose metabolic reprogramming and chemoresistance have provided promising prospects for CRC. Elucidating the interaction and possible mechanism between ncRNAs and metabolic reprogramming has shed some insights into understanding the pathogenesis and drug resistance mechanisms of CRC. Novel biomarkers for the diagnosis, chemoresistance intervention and prognosis prediction of CRC can be investigated in more future studies. Most importantly, it is urgent to search for sufficient evidence supporting the practical clinical applications of ncRNAs in CRC.

**Author contributions**

SY, DX and ZG designed the manuscript. SW, WD, JC, SY and XW performed literature research and drafted the article. MC, DX and ZG revised the review. All authors have read and approved the final article. All authors contributed to the article and approved the submitted version.

**Funding**

This study is funded by National Natural Science Foundation, China (82003042, 82171790, and 81870237), and Natural Science Foundation of Shandong Province, China (ZR2020KC001).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**References**

1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. *CA Cancer J Clin* (2020) 70:145-64. doi: 10.3322/caac.21601
2. Miller KD, Fidler-Benoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. *CA Cancer J Clin* (2020) 70:443–59. doi:10.3322/caac.21637
3. Shen Y, Sun M, Zhu J, Wei M, Li H, Zhao P, et al. Tissue metabolic profiling reveals major metabolic alteration in colorectal cancer. *Mol Omics*. (2021) 17:164-71. doi:10.1039/d1mo00022e
4. Nannini G, Meoni G, Amedei A, Tenori L. Metabolomics profile in gastrointestinal cancers: Update and future perspectives. *World J Gastroenterol* (2020) 26:2514–32. doi:10.3748/wjg.v26.i20.2514
5. Shang S, Ji X, Zhang L, Chen J, Li C, Shi R, et al. Macrophage ABHD5 suppresses NFκB-dependent matrix metalloproteinase expression and cancer metastasis. *Cancer Res* (2019) 79:5513–26. doi:10.1158/0008-5472.CAN-19-1059
6. Jung G, Hernandez-Illan E, Moreira L, Balague F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. *Nat Rev Gastroenterol Hepatol* (2020) 17:111–30. doi:10.1038/s41575-019-0230-y
7. Chan JJ, Tay Y. Noncoding RNA:RNA regulatory networks in cancer. *Int J Mol Sci* (2018) 19:1310. doi:10.3390/ijms19051310
8. Tang J, Yan T, Bao Y, Shen C, Yu C, Zhu X, et al. LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-myc. *Nat Commun* (2019) 10.3499. doi:10.1038/s41467-019-11447-8
miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.

miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer through reprogramming metabolism. The progression via reprogramming metabolism.
Colorectal cancer organoids. HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived organoids targeting the miR-144-3p-PDK4 axis. In vitro, HIF-1α promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit. Front Oncol (2020) 10:274. doi: 10.3389/fonc.2020.00274

Gao T, Liu D, Peng S, Wang M, Li Y. A positive feedback loop of IncRNA MIR3HG-miR-361-3p – Y11 accelerates colorectal cancer progression through modulating proliferation, angiogenesis, and glycolysis. Front Oncol (2021) 11:684984. doi: 10.3389/fonc.2021.684984

Wang Y, Yu G, Liu Y, Xie L, Ge J, Zhan G, et al. Hypoxia-induced PTTG3p contributes to colorectal cancer glycolysis and M2 phenotype of macrophage. Biosci Rep (2021) 41:BSR202101764. doi: 10.1042/BSR202101764

Hong J, Gao F, Su SY, Chen C, Ma D, Zhang X, et al. Nucleus targets IncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer. Gut (2021) 70:2123–27. doi: 10.1136/gutjnl-2020-322780

Shi H, Li K, Feng J, Zhang X. Overexpression of long non-coding RNA urorhabdad-associated 1 causes paclitaxel (Taxol) resistance in colorectal cancer cells by promoting glycolysis. J Chemother (2021) 33:409–19. doi: 10.1186/s12009-021-190632

Yan T, Shen C, Jiang P, Yu C, Gao F, Tian X, et al. Risk SNP-induced IncRNA-SLC5C1 drives colorectal cancer through activating glycolysis signaling. Signal Transduct Target Ther (2021) 6:70. doi: 10.1038/s41392-020-00446-7

Chen C, Wei M, Wang C, Sun D, Li P, Zong X, et al. Long noncoding RNA KNCQUOT1 promotes colorectal carcinogenesis by enhancing aerobic glycolysis via hexokinase-2. Aging (Albany NY). (2020) 12:11685–97. doi: 10.18632/aging.103334

Li S, Zha K, Liu G, Gu J, Niu H, Guo J. IncARSR sponges miR-34a-5p to promote colorectal cancer invasion and metastasis via hexokinase-1-mediated glycolysis. Cancer Sci (2020) 111:3938–52. doi: 10.1111/cas.14617

Zhang Z, Yang W, Li N, Chen X, Ma F, Yang J, et al. LncRNA MCF2L-AS1 aggravates proliferation, invasion and glycolysis of colorectal cancer cells via the crosstalk with miR-874-3p/FOXM1 signaling axis. Aging (Albany NY). (2020) 12:11685–97. doi: 10.18632/aging.103334

Yu Z, Wang Y, Deng J, Liu D, Zhang L, Shao H, et al. Long non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-545-3p/hypoxia inducible factor 1 alpha subunit axis. Bioengineered. (2021) 12:6251–63. doi: 10.1080/21655979.2021.1969833

Zheng H, Zhang M, Ke X, Deng X, Li D, Wang Q, et al. LncRNA XIST/miR-137 axis strengthens chemoresistance and glycolysis of colorectal cancer cells by hindering transformation from PKM2 to PKM1. Cancer biomark (2021) 30:395–406. doi: 10.3233/CBM-201740

Liu S, Huang F, Ye Q, Li Y, Chen J, Huang H. SPRY4-IT1 promotes survival of colorectal cancer cells through regulating PKD1-mediated glycolysis. Anim Cells Syst (Seoul). (2020) 24:220–7. doi: 10.1007/19768354.2020.1784274

Fan Z, Yan S, Sun K, Liu A, Liu S, Wang X. The interaction between IncRNA SNR06 and hnRNPA1 contributes to the growth of colorectal cancer by enhancing aerobic glycolysis through the regulation of alternative splicing of PKM. Front Oncol (2020) 10.363. doi: 10.3389/fonc.2020.00363

Cui S, Yang X, Zeng L, Zhao Y, Yan W. LncRNA MAPF1-AS1 promotes the progression of colorectal cancer by sponging miR-147b and activation of NDUFA4. Biochem Biophys Res Commun (2018) 506:231–8. doi: 10.1016/j.bbrc.2018.10.112

Bian Z, Zang J, Li M, Feng Y, Wang X, Zhang J, et al. LncRNA-FEZF1-A1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clin Cancer Res (2018) 24:4808–19. doi: 10.1158/1078-0432.CCR-17-2967

Wang C, Li Y, Yan S, Wang H, Shao X, Xiao M, et al. Interactome analysis reveals that IncRNA HULC promotes aerobic glycolysis through LDHA and PKM2. Nat Commun (2020) 11:1362. doi: 10.1038/s41467-020-16966-3

Shi H, Li K, Feng J, Fang Z. LncRNA-DANCR interferes with miR-125b-5p/IRB2 axis to desensitize colon cancer cells to cisplatin via activating anerobic glycolysis. Front Oncol (2020) 10.1034. doi: 10.3389/fonc.2020.01034

Li Z, Yao H, Wang S, Li G, Xu C. CircTADA2A suppresses the progression of colorectal cancer via miR-374a-3p/KLF14 axis. J Exp Clin Cancer Res (2020) 39:160. doi: 10.1186/s13046-020-01646-7

Wang X, Tao G, Huang D, Liang S, Zheng D. Circular RNA NOX4 promotes the development of colorectal cancer via the microRNA4855p/KCSB1 axis. Oncol Rep (2020) 44:2009–20. doi: 10.3892/or.2020.7758

Liu Y, Li H, Ye X, Ji A, Fu X, Wu H, et al. Hsa_circ_0008231 knockdown inhibits the glycolysis and progression of colorectal cancer cells by regulating miR-502-5p/MY06 axis. World J Surg Oncol (2020) 18:255. doi: 10.1186/s12957-020-02030-0

Yi B, Dai K, Yan Z, Yin Z. Circular RNA PLLCE1 promotes epithelial mesenchymal transformation, glycolysis in colorectal cancer and M2 polarization of tumor-associated macrophages. Bioengineered. (2021) 13:6243–56. doi: 10.1080/21655979.2021.2030929

Jiang Z, Hu H, Hu W, Hou L, Liu Z, Wu Y, et al. Circ-RNF121 regulates tumor progression and glucose metabolism by miR-1224-5p/FCK1 in colorectal cancer. Cancer Cell Int (2021) 21:596. doi: 10.1186/s12935-021-02290-3

Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T, et al. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PMK2 axis in colorectal cancer. Mol Oncol (2020) 14:539–55. doi: 10.1016/j.omc.2018.07.12629

Zhang Z, Zhang YH, Qin XJ, Wang YX, Fu J. Circular RNA circDENND4C facilitates proliferation, migration and glycolysis of colorectal cancer cells through miR-760-GLUT1 axis. Eur Rev Med Pharmacol Sci (2022) 26:2387–400. doi: 10.26355/eerm-202003_20506

Gao Y, Liu C, Xu X, Wang Y, Jiang Y. Circular RNA sterile alpha motif domain containing 4A contributes to cell 5-fluorouracil resistance in colorectal cancer by regulating the miR-545-3p/hp3-phosphofructo-2-kinase/fructose-2,6-bisphosphatase type 3 axis. Anticancer Drugs (2022) 33:533–63. doi: 10.1097/CAD.00000000000001285

Li Q, Wang Y, Wu S, Zhou Z, Ding X, Shi R, et al. CircACC1 regulates assembly and activation of AMPK complex under metabolic stress. Cell Metab (2019) 30:157–73.e7. doi: 10.1016/j.cmet.2019.05.009

Zhang Y, Mao Q, Xia Q, Cheng J, Huang Z, Li Y, et al. Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers. J Hematol Oncol (2021) 14:169. doi: 10.1186/s13045-021-1179-y